GlobeNewsWire
07 Jun 2026, 23:30 UTC · 13h ago
LENZ Therapeutics Announces Everest Medicines Acquired Rights to Develop and Commercialize VIZZ® (LNZ100) in Greater China
GlobeNewsWire
07 Jun 2026, 23:30 UTC · 13h ago
Story key points
3 claims · impact-rated
Everest Medicines has acquired the rights to develop and commercialize VIZZ (LNZ100) in Greater China via an Asset Purchase Agreement with Corxel Pharmaceuticals. — Expanding a drug's commercial footprint into the massive Greater China market provides a significant growth catalyst for the asset's overall value.
+0.60LENZ Therapeutics is eligible to receive up to $85 million in regulatory and sales milestones, plus tiered royalties on net sales in Greater China. — Directly impacts LENZ's future cash flows and balance sheet through guaranteed milestones and long-term royalty streams.
+0.50The New Drug Application (NDA) for LNZ100 in China was submitted in September 2025, with approval anticipated in Q1 2027. — Provides a clear regulatory timeline for the next major value-inflection point, though the date is still some time away.
+0.30Ticker attribution
Continue reading
6 related stories
Top 1 mover · tap to explore
Model heads
The company is eligible for up to $85 million in milestones and royalties following the asset purchase agreement for VIZZ in Greater China.
Everest Medicines expanded its strategic focus in ophthalmology by acquiring the rights to a differentiated asset with strong commercial potential.
Early access
News Impact Screener scores every headline against the stocks it moves — before the chart reacts. Join the early-access list and get alerted the moment a story hits your tickers.
Impact vectors
5 dimensions · 9 clusters
Market reaction
10 bid · 0 offered
No stock impact ranking available yet.
